TD Waterhouse Canada Inc. Trims Position in Danaher Corporation $DHR

TD Waterhouse Canada Inc. decreased its stake in shares of Danaher Corporation (NYSE:DHR) by 3.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,393 shares of the conglomerate’s stock after selling 2,639 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Danaher were worth $15,755,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of DHR. Primecap Management Co. CA boosted its holdings in shares of Danaher by 924.2% in the second quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock valued at $244,815,000 after purchasing an additional 1,118,318 shares during the period. Perennial Investment Advisors LLC lifted its holdings in shares of Danaher by 21.1% in the 2nd quarter. Perennial Investment Advisors LLC now owns 3,344 shares of the conglomerate’s stock worth $661,000 after buying an additional 582 shares during the period. Empowered Funds LLC grew its position in shares of Danaher by 58.8% during the 2nd quarter. Empowered Funds LLC now owns 24,129 shares of the conglomerate’s stock worth $4,766,000 after buying an additional 8,934 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after buying an additional 788,499 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. raised its holdings in shares of Danaher by 13.9% in the second quarter. Pinnacle Wealth Planning Services Inc. now owns 3,296 shares of the conglomerate’s stock valued at $651,000 after acquiring an additional 402 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 33,026 shares of company stock valued at $7,195,987. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Shares of DHR opened at $222.58 on Thursday. The company has a 50 day moving average of $207.29 and a two-hundred day moving average of $201.61. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The company has a market cap of $157.22 billion, a price-to-earnings ratio of 45.89, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.71 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on DHR shares. Robert W. Baird set a $247.00 target price on shares of Danaher in a report on Wednesday, October 22nd. Barclays increased their price objective on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Finally, Rothschild Redb cut Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Eighteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.